Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for success  by Rekers, Niels V. et al.
Clinical Immunology 161 (2015) 37–43
Contents lists available at ScienceDirect
Clinical Immunology
j ourna l homepage: www.e lsev ie r .com/ locate /yc l imImmunotherapies and immune biomarkers in Type 1 diabetes: A
partnership for successNiels V. Rekers a,b, Matthias G. von Herrath a, Johnna D. Wesley a,⁎
a Type 1 Diabetes R&D Center, Novo Nordisk Inc., Seattle, WA, USA
b Paciﬁc Northwest Diabetes Research Institute, Seattle, WA, USAAbbreviations: ELISpot, enzyme-linked immunosorb
Drug Administration; HbA1c, hemoglobin A1c; NOD, non-
MHC; SoC, standard of care; T1D, Type 1 diabetes.
⁎ Corresponding author at: Type 1 Diabetes R&D Ce
Fairview Avenue North, Seattle, WA 98109, USA.
E-mail address: JoWy@NovoNordisk.com (J.D. Wesley
http://dx.doi.org/10.1016/j.clim.2015.05.021
1521-6616/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 19 March 2015
Received in revised form 13 May 2015
Accepted with revision 17 May 2015
Available online 27 June 2015
Keywords:
Type 1 diabetes
Immunotherapy
BiomarkersThe standard of care (SoC) for Type 1 diabetes (T1D) today is much the same as it was in the early 1920s, simply
with more insulin options—fast-acting, slow-acting, injectable, and inhalable insulins. However, these
well-tolerated treatments only manage the symptoms and complications, but do nothing to halt the underlying
immune response. There is an unmet need for better treatment options for T1D that address all aspects of the
disease. For decades, we have successfully treated T1D in preclinical animal models with immune-modifying
therapies that have not demonstrated comparable efﬁcacy in humans. The path to bringing such options to the
clinic will depend on the implementation and standard inclusion of biomarkers of immune and therapeutic
efﬁcacy in T1D clinical trials, and dictate if we can create a new SoC that treats the underlying autoimmunity
as well as the symptoms it causes.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Type 1 diabetes (T1D) is a chronic metabolic disorder that results
from autoimmune-mediated inﬁltration and destruction of the pancre-
atic islets [1]. This disease is characterized by the gradual emergence of
pancreas-speciﬁc autoantibodies and severe hyperglycemia, and
frequently associated with serious health complications [2,3]. It can be
diagnosed at any age, regardless of sex, though it is most associated
with children and adolescents [4].Much of our understanding of the im-
munopathology of T1D has been gained through extensive studies of
the non-obese diabetic (NOD) mouse model. The disease that develops
in this model occurs spontaneously and is autoimmune-driven [5].
It was long believed that, at diagnosis, patients had lost themajority,
if not all, of theirβ cell function; thiswas supported bynumerous in vivo
studies and by the surrogatemeasurements used to determine function,
i.e., stimulated C-peptide and hemoglobin A1c (HbA1c) [1,6]. However,
recentwork usingmore sensitive C-peptidemeasurements has demon-
strated that many patients have detectable β cell function at diagnosis
and that individuals with long-standing diabetes retain some insulin
production capacity [7]. This suggests that β cells may be recoverable
and T1D could be reversible, especially if diagnosed early [8]. Additionalent spot assay; FDA, Food and
obese diabetic; pMHC, peptide-
nter, Novo Nordisk, Inc., 530
).
. This is an open access article understudies, in large part from the Network of Pancreatic Organ Donors and
associated investigators, have elegantly shown the variability in and
rarity of detectable immune inﬁltration and β cell mass at diagnosis
and beyond [9,10].
Current approved treatment options are limited to mostly insulin
replacement, which is dependent on estimation of insulin need following
meals and activities, and on constant monitoring of blood glucose levels
[11]. Other emerging therapies hope to improve glucose uptake via im-
proving insulin sensitivity or increasing insulin secretion and decreasing
glucagon [12–14]. These treatments focus on improving and/ormaintain-
ing glycemic control but do little to dampen the underlying immune
response or address the immune defect orchestrating β cell death and
dysfunction. Development of immunotherapeutics to cure or prevent
T1D represents one of the greatest medical challenges of our era—and
the development of tools to understand their impact remains a hurdle
to implementation of such therapies in the clinic. T1D represents a signif-
icant ﬁnancial and emotional burden on society [15], and there is an
unmet need for better treatment options that address all aspects of the
disease. With this review, we provide an overview of the hurdles in
developing immunotherapies and bringing them to market, and the
role of immune biomarkers as tools for the prediction, progression, and
validation of therapeutic responses in T1D.
2. Immunotherapies for T1D: a complicated road to the clinic
Immune modiﬁcation holds signiﬁcant therapeutic promise for
cancer [16], allergy [17], and autoimmunity [6,18], aswell as challenges.
Developing immunotherapies for T1D has been difﬁcult in part tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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medical community at-large that fails to account for the heterogeneous
nature of T1D and differences in immune status between children and
adults [9,19]. Additionally, the discordance of efﬁcacy in preclinical
models with the reality in human populations, the lack of validated im-
mune biomarkers that facilitate translation from preclinical to clinical
[20–22], and the lack of distinction of safety, immune efﬁcacy, and
therapeutic efﬁcacy [11,19] have had a negative impact on T1D
immunotherapies. Collectively, these developmental road blocks have
slowed progression of new treatments to the clinic and often resulted
in disappointing clinical trial results.
2.1. Preclinical challenges
Over the last 30 years, numerous NOD studies have investigated the
impact of both systemic, non-antigen-speciﬁc immune-modulators as
well as antigen-speciﬁc therapies on the diabetes-associated immune
response [5,22]. This preclinical model has been critical to our under-
standing of autoimmune diabetes yet there are caveats that have
complicated translating efﬁcacy into the clinic including differences in
β cell replication; islet structure; severity and composition of the
immune inﬁltrate in the islets; and the main T-cell subset involved
[21]. In fact, diabetes can be prevented or cured in the NOD, yet we
have not seen such successes in human studies [20–22]. Often, the
interpretation of efﬁcacy is complicated by the prevalent low-rate of
reproducibility associated with published preclinical results. This is, in
part, due to the shortage of GMP-sourced compounds for preclinical
testing, variability in methods used for analyses, and what is shared in
publications. Further, most preclinical studies fail to resemble, in any
way, studies conducted in clinical settings.Many animal studies, usually
with small numbers of animals per group (b10/group), start treatment
before insulitis begins or the day hyperglycemia is conﬁrmed. This is not
possible in the clinic as we have little guidance as to when insulitis
begins and treatment immediately at diagnosis is complicated, and for
immunotherapies, may be too late. Also, often only one sex of mice
are treated and all mice in a given cage are given the same treatment
rather than randomizing treatments across multiple cages or involving
both sexes when possible. Additionally, the lack of immune biomarkers
that can move from mouse to man as the compound moves through
development only further hinders this translation—this is discussed
further in Section 3.
As mentioned earlier, T1D can occur at any age, which further
complicates the bench-to-bedside translation of immune-modifying
compounds [23,24]. It is entirely reasonable to assume that the disease
in the young is immunopathologically distinct from diabetes in adults—
these may very well be two distinct diseases. This may signiﬁcantly
change how T1D should be treated and underlie the high failure rate
in phase II and III trials.
Although advances in diabetes standard of care (SoC) have dramat-
ically increased glycemic control and improved quality of life, it does
not match the precision of β cell-mediate glucose regulation nor
completely prevent diabetes-associated complications [25]. However,
to replace or even supplement current SoC, which is safe and generally
well-tolerated, with an immunotherapy, it must be effective, long-
lasting, and have minimal side effects. Currently, there are over 1000
open clinical trials being conducted involving T1D patients listed on
Clinicaltrials.gov, many investigating new types of insulin or glucose
monitoring technology. A review of the ﬁrst 150 listed showed that
10% involved an immune-modiﬁer tested in children as young as 4
and adults up to 45 years of age. The promise of immunotherapies for
the treatment of T1D has been demonstrated in trials investigating
T-cell-targeted or -selective compounds, such as teplizumab, alefacept,
and abatacept, though they have failed to meet their trial endpoints or
provide sustained beneﬁt that outweighs the potential risk [26–29].
These near-misses support the need for better indicators of response,
patient identiﬁcation, and combination options, and highlight thechallenges for moving such therapies to market. This section was not
meant to be a comprehensive discussion of the challenges of developing
immune-modifying therapies for T1D but to promote on-going discus-
sion among researchers and regulatory bodies.
3. Biomarkers: measures of risk, progression, and response
3.1. Primary disease-speciﬁc biomarkers
The standard biomarkers favored by regulatory agencies like the
Food and Drug Administration (FDA) and most familiar to investigators
are disease-associated, e.g., insulin usage, HbA1c, and C-peptide, and
provide little insight to the diabetes-associated immune response [2,
30,31]. In the 2008 draft guidance on diabetes trials, the FDA recom-
mended that such trials have a primary endpoint of reduction in
HbA1c ormaintenance of C-peptide from baseline [31]. HbA1c is formed
in a non-enzymatic glycation pathway when hemoglobin is exposed to
glucose, and serves as amarker for the average blood glucose levels over
a 3–4 month period [30]. When the average blood glucose level
increases, HbA1c increases in a predictable way and is a fairly stable
clinicalmarker ofmetabolic control, with little intra-individual variability.
C-peptide is excised from proinsulin to generate biologically active
insulin; it is used to assess endogenous insulin secretion either in a
fasting or non-fasting sample or in a stimulation test using either
intravenous glucagon or a standardized mixed meal tolerance test,
with latter being the most accurate [32]. A decline in stimulated
C-peptide is indicative of reduced insulin production and progression
of diabetes [33]. Notably, C-peptide levels are variable among patients
and will be impacted by renal complications. Also, the rate of decline
in T1D is heterogeneous, and dependent on age, level at diagnosis,
gender, and season [34]. Subsets of people have been shown to have
residual C-peptide for years after diagnosis. The rate of decline may be
a valuable predictor of therapeutic response, perhaps even aid in
identifying patients with recoverable β cell function, and be a valuable
stratiﬁcation measure in a trial setting [35]. While these measures
provide clear information regarding clinical outcome, they offer no
guidance to the effectiveness of a given immunotherapy, especially
when it fails to impact these clinical markers—was it because the com-
pound did not affect the intended pathway or because the pathway
does not affect disease? Clinical and disease markers are important
tools for measuring and comparing treatment effects in T1D trials;
however, their usefulness is limited to assessing improvement of
glycemic control. They do not reﬂect disease onset or changes in the
underlying immunopathology, or even, truly, the complexity and hetero-
geneity of T1D. By the time of diagnosis, the autoimmune process is
well-established, perhaps even beginning to wane as antigen availability
decreases, and months, or even years, may have passed since the smol-
dering immune attack began.
3.2. Genetic markers
More than 40 genetic loci have been associated with T1D onset [11,
36,37], both protective and predisposing. Themost striking associations
with T1D, accounting for about 50% of the genetic susceptibility/risk
alleles, are located in the human leukocyte antigen (HLA) region [11,
38]. HLA-DR and HLA-DQ class II loci regions have the strongest
association with T1D onset; the DR3/4-DQ2/8 heterozygous haplotype
confers the greatest susceptibility [39,40]. This high-risk haplotype is
present in 30–50% of patients with T1D but only in ~2% of the general
population. Combined with islet-speciﬁc antibodies, the DR3/4-DQ2/8
genotype may identify to subgroups with N75% disease risk [41–43].
Association studies have also uncovered HLA class II genotypes
(DRB1*1501 and DQA1*01012-DQB1*0602) that confer dominant
protection against T1D [38,43]. In addition to class II, HLA class I loci
also inﬂuence risk for T1D. Most of the residual association can be
attributed to HLA-A (e.g., HLA-A*02, -A*24) and HLA-B (e.g., HLA-B*18,
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dent of the class II alleles [44], and the associated disease risk is substan-
tially less prominent than for HLA class II loci. As a result, HLA class I
alleles have not been incorporated into risk prediction models. Of the re-
maining susceptibility loci, only those for the insulin (INS VNTR), PTPN22,
IL2RA, and CLTA4 genes are associated with odds ratios greater than 1.1
for T1D onset [37]. The advent of next generation sequencing (NGS) tech-
nologies has facilitated accurate and parallel sequencing of long human
genomic sequences. Implementation of NGS in clinical trials permits
low cost, high throughput screening for T1D susceptibility loci [45,46].
Collectively, the genes aremost valuable as markers of inclusion and, po-
tentially, of predicted therapeutic response.
3.3. Immune biomarkers for safety & immune efﬁcacy
Of the 15 or so trials (~10% of the 150 current open trials) that are
currently investigating immunotherapies in T1D mentioned in
Section 2.1, fewer than half included any immune endpoints—though
immune biomarkers are recommended by the FDA for trials investigat-
ing immune-modifying drugs in diabetes [31]. Immune biomarkers
provide an indicator of pathway engagement, a measurement that is
important even if a therapy fails to show clinical efﬁcacy. They may
also reveal safety concerns quickly, such as increased autoimmunity,
excess immunosuppression that results in increased infections or risk
of cancers, or increased inﬂammation. In addition, they may aid in
identifying appropriate patient populations that should be included or
excluded from a study [47]. This would be especially valuable in
antigenic therapy trials where inclusion of subjects with reactivity to
the test antigen may inﬂuence outcome.
The hurdles in developing and optimizing an immune biomarker are
many. First, sample volumes preclude extensive peripheral biomarker
development in mice while target tissue samples for immune biomark-
er development are extremely limited in humans [48,49]. Also,
autoreactive responses in the periphery are rare and often require
signiﬁcant ex vivo manipulation. Additionally, systemic signatures that
may be an accurate depiction of response can potentially be vetted
easily in mice but we must rely on our best models or limited data
from trials with healthy or diabetic individuals for conﬁrmation in
humans. And, ﬁnally, variability between performing labs, reagent
sources, and control usage greatly impact results and utility.
The NOD model has been a valuable tool for understanding disease
mechanisms and teasing out the relevance of potential therapeutic
targets. The involvement of the immune system, especially CD4
T-cells, is clear in the NOD; years of work in hundreds of labs have
shown this repeatedly [21]. In the human disease, however, the amount
of supporting evidence is less signiﬁcant but convincing. There is a clear
immune component in human T1D—evidence of autoreactive cells in
circulation and in tissue, HLA-association, and the diagnostic value of
autoantibodies support this [11]. A number of immune biomarkers
have been pursued in the NOD, including Treg to effector ratios,
CD4-dependent cytokine responses, frequency of disease-speciﬁc CD8
and CD4 T-cells, circulating cytokines, antigen presenting cell activation
status and frequency, and autoantibody titers. Often, these are
measured using splenic tissue, lymph nodes, or pancreatic tissue rather
than blood or serum [50–52]. Immune biomarkers requiring any tissue
other than blood will be challenging to translate to human populations.
Thus, beyond autoantibodies measured in serum or plasma, there are
currently no immune biomarkers that provide value in both the
mouse and human disease and translate from bench to bedside, which
creates a gap that will continue to hinder the development of immuno-
therapies for T1D. There is also a lack of information regarding immune
biomarker variability in humans, and the ability to reﬁne immune
biomarker strategies in relevant humanpopulations is currently limited.
Greater support from regulatory agencies for phase Ia or IIa trials that
are designed to investigate mechanism and identify immune
biomarkers that correlate with response could aid in the developmentof a clinical strategy thatwould take into consideration safety, therapeutic
efﬁcacy, and immune efﬁcacy, and create a ‘Response Signature’ [31].
This would give a broader picture of the efﬁcacy of immunotherapies
in T1D.
For a marker to be broadly applicable in a clinical setting it must be
measurable in the periphery—rather than detectable in spleen, pancre-
as, or lymph nodes—but be representative of the disease-associated
immune response, and it must be usable with a small-volume sample.
Additionally, a validated method for sample preparation and a
standardized and validated assay protocol, including documentation of
reagent quality, are also required [53]. Best case, it would also be
inexpensive, use widely-available technology that is ‘user-friendly’,
and eventually function as a surrogate marker of clinical outcome to
replace C-peptide or HbA1c. If you are designing the optimal marker,
why not think big? Yet, currently, even our best options do not meet
most of this criteria; the technology has not yet evolved to make these
‘best case’ biomarkers a reality. There are a few that are promising but,
currently, far from optimal and they focus on autoantibodies (AAbs)
and T-cells.
3.3.1. Autoantibodies—speciﬁcity and isotype
Islet-speciﬁc AAbs have been correlated with T1D for over 40 years
and are an indicator of β cell-directed autoimmunity. They are used to
differentiate T1D from the more common Type 2 diabetes (T2D) and
help stratify disease risk in individuals with a family history and predis-
posing HLA. In fact, among children positive for N2 AAbs, 70% will be
diagnosed with T1D in less than 10 years; and being positive for ≥3
AAbs, even without a family history, is highly predictive of diagnosis
[54]. AAbs are often detected years before diagnosis and the most
common are speciﬁc for insulin (IAA) [55], insulinoma-associated
antigen-2 (IA-2) [56], 65 kDa glutamic acid decarboxylase (GAD65)
[57–59], or zinc transporter 8 (ZnT8) [60], with IAA often occurring
ﬁrst. They can be measured in the serum, plasma, or saliva, and are
incredibly stable biomarkers. A number of global harmonization efforts
over the last couple of decades, including the Diabetes Autoantibody
Standardization Program (DASP), have helped identify the most
sensitive and speciﬁc assay methods; determine reference standards
and optimal antigens; and highlight best practices and top-performing
labs, as well as underscore the weaknesses associated with different
methods [61,62]. These efforts have helped make the measurements
and interpretation of AAbs a standard, reliable practice.
As highlighted by DASP, the assays used for detecting AAbs vary in
sensitivity and speciﬁcity, and include a traditional enzyme-linked
immunosorbent assay (ELISA), a radio immune assay (RIA), and
electrochemiluminescence (ECL) assay [61–63]. ELISA is inadequate
and now rarely used for AAb detection due to high background. RIA is
the most commonly used platform; however, DASP results have
shown overall poor performance and sensitivity. The ECL assay, in
contrast, has consistently demonstrated higher sensitivity for IAA and
anti-GAD—though it is much less widely used [63]. However, none of
these methods are amenable to point-of-care use; each require at least
1-mL whole blood and take days to conduct. A promising new platform
developed by Zhang et al. from Stanford University was recently pub-
lished using plasmonic gold chip for near-infrared ﬂuorescence-
enhanced (NIR-FE) detection of islet speciﬁc AAbs [24]. This plasmonic
chip required less than 2 μL whole blood, equivalent to a ﬁnger prick,
and provides results for IAA, anti-GAD, and anti-IA2 in 2 hours from
assay start.
The usefulness of AAb positivity or titer as an immune marker may
be most obvious as an inclusion criterion to ensure that T1D+ individ-
uals are distinguished from T2D+ and, in the case of antigenic therapies,
that patients without demonstrated reactivity to a given antigen such as
GAD65 are not enrolled in a trial. AAb have not been shown to be path-
ogenic; changes in titers following treatment with an immunotherapy
are not likely indicative of immune efﬁcacy. However, AAb isotype
determination may provide a more speciﬁc measure of immune status
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functions including complement activation and antibody-dependent
cytotoxicity. Current data regarding AAb isotypes in diabetes supports
the prevalence of IgG over IgM for IAA detected in T1D subjects. It is
likely that the initial, early AAb response to a diabetes-associated anti-
gen, such as insulin or GAD, would be IgM; this is seen in non-diabetic
individuals [64]. As the immune response progresses, T-cells would
become involved and isotype switching and afﬁnity maturation would
occur, driving the AAb response to IgG subtypes, indicating disease pro-
gression. However, multiple reports have indicated that the earliest
peak AAb levels detected in the pre-diabetic phase for IAA, GAD, and
IA2 comprise mainly of IgG1. Also, antibodies that develop in response
to exogenous insulin tend to be mostly IgG1 and IgG4 [65,66]. Hoppu
et al. suggested that IAA-IgG1 and -IgG3 were associated with a more
rapid progression to T1D in a subset of children who were part of the
Finnish Type 1 Diabetes Prediction and Prevention Study [67]. It should
be noted that the current assay for detectingAAb isotypes is a sepharose
bead-based RIA and is not currently widely performed or fully opti-
mized. More work is needed to fully validate this assay and standardize
interpretation.
3.3.2. Antigen-speciﬁc T-cells—multimeric pMHC & cellular assays
The most promising immunotherapy clinical trials in T1D to-date
have involved T-cell modulation, either via depletion or forced suppres-
sion [26–29]. Methods to sensitively determine frequency, and perhaps
function, can be technically challenging, costly, and fraught with
background and potential analytical bias [68–73]. Evaluation of both
CD4 and CD8 T-cells provides insight into the immune complexity of
T1D. The repertoire of diabetogenic epitopes is diverse, and the precise
role of particular speciﬁcities in diabetes development and progression
remains unclear [74]. CD4 T-cells provide help, cytokines, and regulation,
while CD8 T-cells produce inﬂammatory cytokines to drive the destruc-
tive immune response forward and kill beta cells [75]. Furthermore,
frequencies of islet antigen-reactive CD4 and CD8 T-cells are higher in
T1D patients compared to healthy subjects, though variable over time,
andmay have the potential to function as a prognosticmarker for disease
onset or treatment response [74,76]. In addition, pMHC multimers may
also providemeans to distinguish betweenT1DandT2D subjects. Though
β cell destruction and evidence for islet autoimmunity have been detect-
ed in patients with T2D [77–79], Sarikonda et al. reported that CD4 T-cell
reactivity to islet antigens was common in both T1D and T2D patients,
while the presence of CD8 T-cell autoreactivity was unique to subjects
with T1D [80]. The major methods used are ﬂow cytometry with HLA
multimers [81,82], and cellular assays such as enzyme-linked immuno-
sorbent spot (ELISpot) and FluoroSpot assays. Multiple groups have
worked tirelessly to optimize these assays and demonstrate their value
in animal models and in humans.
3.4. Multimers & ﬂow cytometry
First reported in Science by Altman et al. in 1996, ﬂuorescently
labeled multimeric peptide-MHC complexes (pMHC or pHLA), either
class I or II, are now widely used for determining the frequency of CD8
or CD4 T-cells, respectively, in a variety of conditions [80,81,83–85].
Direct labeling of the T-cell receptor (TCR) with pHLA multimers
identiﬁes antigen-speciﬁc T-cell subsets without restriction to their
functional competency. This allows for unbiased exploration of the
total pool of T-cells with a distinct speciﬁcity, additional surface and
extracellularmarkers can be included to provide amore detailed picture
of antigen-speciﬁc T-cells. Additionally, both freshly isolated and
cryopreserved peripheral blood mononuclear cells (PBMC) can be
used. pMHC class I multimers have been evaluated and optimized for
detection of anti-viral responses where T-cells are often easily detect-
able and there is a clear separation between positive and negative
populations. As the frequency of autoantigen-speciﬁc T-cells in circula-
tion is very low and often not easily separated fromnegative populations,the quality of the results from multimer-based assays are dependent on
the quality of the sample and cryopreservation, the speciﬁcity of the
reagents, and the competency of the performing lab.
As the ﬁeld of ﬂow cytometry advances, cytometers have become
more sensitive and able to handle more lasers to deﬁne many more
parameters, and the use of multimeric reagents for T-cell studies has
expanded. Numerous workshops and efforts to harmonize the use of
multimers and ﬂow cytometry in HIV/AIDS, oncology, and T1D have
improved the reliability, sensitivity, and speciﬁcity of antigen-speciﬁc
T-cell detection, especially for CD8 subsets [68]. pMHC II multimers
are challenging, in part due to the wide range of pMHC avidity in the
context of autoantigens and low frequency (even less frequent than
CD8) that often require ex vivo stimulation prior to staining or expan-
sion for functional evaluation. Additionally, there are multiple binding
registers associated with long peptides, which can result in distinct
TCR-pMHC interactions and resulting function [69]. The ‘barcoding’
approach to multimer labeling, where the same multimer is prepared
using two (or even more) ﬂuorochromes such as quantum dots, has
enhanced the detection of autoreactive T-cells tremendously, though
not without adding to assay complexity [70].
Despite advancement of technology and methods, there are limita-
tions that need to be addressed before pMHC multimer analyses can
bewidely used in T1D clinical trials. The quality of the data is dependent
on the sample quality; therefore, sample used must be handled with
care and precision, following a validated cryopreservation procedure
using reagents that have been selected for not only cell recovery and
viability but also reactivity, using ELISpot with and without stimulation.
A validated thawing protocol, qualiﬁed reagents, and proﬁcient operators
are also critical. Currently, the primary pMHC multimers available are
HLA-A2-restricted or epitopes of the same antigen (i.e., pre-proinsulin)
for only a few HLA alleles [74], hindering widespread multimer use as
an immune biomarker. In addition, the frequencies of antigen speciﬁc
T-cells in PBMC are very low. Even viral antigen-speciﬁc T cells with
relatively high precursor frequencies are typically of 1% or less, in the
absence of an active infection or response. In order to detect these low
frequencies, large numbers of cells need to be labeled with multimers
and analyzed with markers to exclude unwanted populations from the
analyses (such as anti-CD19 to exclude B-cells; anti-CD14 to exclude
monocytes) and to identify live cells (viability dye). This issue is further
complicated by multimer-induced downregulation of TCRs; this can be
limited by the inclusion of a protein kinase inhibitor that stabilizes TCR
expression [68,86]. Additionally, controls to demonstrate multimer spec-
iﬁcity—primary clones or transfected cells—are crucial to provide a crite-
rion for assessing reagent speciﬁcity batch-to-batch, assay performance,
and operator competency. With regard to batch-to-batch variability con-
cerns formultimeric pMHC preparations, an article published in the early
part of 2015 demonstrated that pMHC multimers can be frozen up to 6-
months [70]. We also recently observed this using a broad range of
diabetes-associated multimers, and stability tests to conﬁrm the length
of storage time allowable are on-going (data not shown). Finally, rigor-
ously validated protocols for multimerization and staining should be
morewide-spread and standards for gating practices should bemore de-
ﬁned and shared in publications such as Cytometry Part A, OptimizedMul-
ticolor Immunoﬂuorescence Panel (OMIPS) [87] and in agreement with
published harmonization recommendations [71,88].
3.5. ELISpot & FluoroSpot
Cellular assays, e.g., ELISpot, have been used for immunemonitoring
for decades, from infectious disease to cancer to diabetes [72,73,89]. The
assay is highly ﬂexible and can be used to evaluate the function of a
variety of cell types, providing both quantitative and functional
information for the cells of interest. The most common version of
ELISpot used is the IFN-γ ELISpot. Antigenic peptides and control stimuli
are used to promote cytokine release by T-cells which is captured
directly on the surface of the culture plate, commonly a nitrocellulose
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measured and the total response quantiﬁed for a measure of immune
reactivity to speciﬁc stimuli. ELISpot is a sensitive assay that can detect
a low frequency of antigen-speciﬁc T cells, i.e., 25 IFN-γ+ T-cells per
million PBMC and perhaps even as low as ten responder cell per million
[72,90].
ELISpot assays have been used to identify cytokine responses to
islet-speciﬁc antigens and distinguish responses in T1D patients and
healthy subjects. Arif et al. demonstrated a signiﬁcant skewing of cyto-
kine responses of T1D-derived samples to an inﬂammatory phenotype
in response to diabetes-associated antigens and a regulatory phenotype
in healthy donor cells incubatedwith the same antigens [91]. Incubation
of PBMCwith a peptide comprising the 9-23 amino acids of the insulin B
chain (B9–23) induced a ten-fold increase in IFNγ-secreting cells in chil-
dren with recent-onset diabetes [92]. In line with these ﬁndings, Arif
et al. also demonstrated in a 2011 publication that peripheral blood
CD4 T-cells from newly diagnosed T1D patients secreted higher levels
of IFNγ and IL-17 in response to β cell antigens, whereas healthy control
subjects produce a characteristic IL-10 response to the same antigen [91,
93]. ELISpot assays have also been included as a secondary endpoint in
the DiaPep277 clinical trial. These results showed that treatment of
adult T1D patients with DiaPep277 induced a shift from T-helper-1 to
T-helper-2 cytokines that seemed to correlate with preservation of
endogenous insulin production [94].
Even though these ﬁndings reﬂect the potential of ELISpot results as
an immune biomarker in T1D research, the current assay can be suscep-
tible to high variation and error. Similar to multimer assays, the ELISpot
assay depends on identiﬁcation of antigenic epitopes. As a result,
inclusion of ELISpot as an endpoint in T1D studies is mainly limited to
use in studies with HLA-DR4+ subjects [93,95]. In addition, the high
sensitivity of the assay may affect both the inter- and intra-assay
reproducibility. Generation of reproducible ELISpot data depends on
validation of the methods for sample preparation, the assay protocol,
the reagent quality, and the operator [96]. When used in T1D studies,
the ELISpot assay is traditionally carried out with freshly isolated
PBMC, which introduces signiﬁcant assay variability and prevents
reproducibility with the same time-point sample. This also poses a
signiﬁcant burden on the operating lab and is a serious hindrance to
inclusion of this assay in T1D clinical trials as an immune endpoint.
The use of this assay outside of T1D has more frequently been with
cryopreserved samples and extensive work has been conducted to
evaluate optimal cryopreservation and thawing practices that limit
functional loss [97,98]. Standardized freezing protocols have been
developed that facilitate cryopreservation of PBMC such that, upon
thawing, the cells maintain their full functionality in cytokine ELISpot
assays [98]. Additionally, global harmonization efforts to provide guid-
ance on best practices and operator proﬁciency have been on-going in
T1D and oncology to optimize the utility and reproducibility of ELISpot
results [71,72,88,99,100].
Further, potential sample limitations associated with human
samples can be addressed by development of multi-analyte cellular
assays and could enhance the usefulness of ELISpot. Early attempts in
the development of multiplex ELISpot assays focused detection of two
analytes using combinations of enzymes and substrates to generate
different colored substrate products on the same plate [101,102].
Thus, single secreting cells would give either blue (alkaline phospha-
tase) or red (horseradish peroxidase) spots, while double secreting
cells would produce purple colored spots. However, interpretation of
these dual color spots has proven difﬁcult, as one color is easily
obscured by a stronger spot in the second color. The recent introduction
of the FluoroSpot assay—which relies on ﬂuorophores instead of
enzyme-substrate combinations for the visualization of cytokine secre-
tion—facilitates the distinct analysis of two or more analytes in a single
well [103,104]. Even though the current FluoroSpot assay is comparable
to the ELISpot, there is room for further improvement in the form of
new ﬂuorophores, ﬂuorescence enhancers, and automated readers.Notably, the ability to perform triple-analyte assays is quickly becoming
a reality [104].
4. Conclusions
The validity of immunotherapies for the treatment of T1D has
been demonstrated in preclinical studies and supported with data
from human samples. Additionally, the requirement for immune
biomarkers is clear from numerous clinical trials assessing—and
rejecting—immunotherapies in T1D using traditional response
criteria. The area of immune biomarkers is expanding and has broad
implications beyond T1D. To move this area forward across disease set-
tings, it will be critical for regulatory agencies, industry, and academic
institutes to work together to deﬁne expectations of immune efﬁcacy
and provide guidance on best practices for implementing assays to
reproducibly measure immune biomarkers.
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